Idiopathic pulmonary fibrosis is a prototype of chronic, progressive, and fibrotic lung disease.
Healthy tissue is replaced by altered extracellular matrix and alveolar architecture is …

Oxidative stress, which results in the damage of diverse biological molecules, is a ubiquitous
cellular process implicated in the etiology of many illnesses. The sulfhydryl-containing …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung
disease, characterised by progressive scarring of the lung and associated with a high …

Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pulmonary
disease with a median survival of 2–4 years after diagnosis. A significant number of IPF …

Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease characterized by an
abnormal reepithelialisation, an excessive tissue remodelling and a progressive fibrosis …

Fibrotic interstitial lung disease (ILD) represents a large group of pulmonary disorders that
are often progressive and associated with high morbidity and early mortality. Important …

Pirfenidone is one of two approved therapies for the treatment of idiopathic pulmonary
fibrosis (IPF). Randomised controlled clinical trials and subsequent post hoc analyses have …

Objective There is a paucity of observational data on antifibrotic therapy for idiopathic
pulmonary fibrosis (IPF). We aimed to assess the course of disease of IPF patients with and …

Although fibrosis is a final pathological feature of many chronic diseases, few interventions
are available that specifically target the pathogenesis of fibrosis. Natural products are …

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease with limited
therapeutic options, and there is a huge unmet need for new therapies. A growing body of …